RxDoctor Payments Data

Mariann Alperin

Urogynecology and Reconstructive Pelvic Surgery · Encinitas, CANPI 1033266879

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (46.6%), education and travel and lodging — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Intuitive Surgical at 50.1% of the total. Reporting peaked in 2023 at $8,994 and has fallen 97.6% since, to $217 in 2025.

$17,697in general payments, 2019–2025

Across 39 payments — averaging $453.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$9K
  • Renovia Inc$8K
  • AbbVie$197
  • Coloplast$100
  • Medtronic$69
  • Baxter Healthcare$64
  • plus $148 from 3 others

What the payments were for

  • Consulting fees$8,25047%
  • Travel & lodging$1,3267%
  • Food & beverage$6204%
  • Education$7,50042%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,697 in reported general payments places this provider in the 85th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.

See all urogynecology and reconstructive pelvic surgery providers in California

Medicare billing

Part B allowed, 2024
$75,530
Medicare patients
133
Services billed
2,233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron64$57,861
GemtesaVibegron31$24,571
Estradiol94$8,068
EstringEstradiol12$6,040
YuvafemEstradiol23$4,067
Methenamine Hippurate22$2,984
Trospium Chloride ErTrospium Chloride12$1,789
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst23$215

Paid to pharmacies, not to this prescriber.

Other urogynecology and reconstructive pelvic surgery in Encinitas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →